Advertisement

<a href="//cdm-d.openx.net/w/1.0/rc?cs=ede153ebee&cb=INSERT_RANDOM_NUMBER_HERE"> <img src="//cdm-d.openx.net/w/1.0/ai?auid=538187993&cs=ede153ebee&cb=INSERT_RANDOM_NUMBER_HERE" border="0" alt=""></a>

#VRC01

Trevor Crowell, MD, at IAS 2017

Experimental Antibody Delays but Does Not Prevent HIV Rebound

People treated with VRC01 maintained undetectable viral load for up to 42 weeks after stopping antiretroviral therapy.

The FDA approved Truvada for use as HIV prevention on July 16, 2012.

As PrEP Turns Five, the HIV Prevention Pill Is a Major Success

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

HIV Vaccine Research in Mice Shows Promise

Scientists succeed with new methods of spurring the immune system to manufacture broadly neutralizing antibodies against the virus.

Prevention: Antibody Infusions

A future form of pre-exposure prophylaxis (PrEP) may be an antibody infusion given every other month.

Advertisement

<a href="//cdm-d.openx.net/w/1.0/rc?cs=ede153ebee&cb=INSERT_RANDOM_NUMBER_HERE"> <img src="//cdm-d.openx.net/w/1.0/ai?auid=538187994&cs=ede153ebee&cb=INSERT_RANDOM_NUMBER_HERE" border="0" alt=""></a>